Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy

Bonneterre,J.; Révillion,F.; Desauw,C.; Blot,E.; Kramar,A.; Fournier,C.; Hornez,L.; Peyrat,J.  P.

doi:10.3892/or.2012.2090

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy

Authors:
- J. Bonneterre
- F. Révillion
- C. Desauw
- E. Blot
- A. Kramar
- C. Fournier
- L. Hornez
- J. P. Peyrat
View Affiliations

Affiliations: Oscar Lambret Center, F-59000 Lille, France, Regional University Hospital, F-59037 Lille Cedex, France, Henri Becquerel Center, F-76038 Rouen Cedex, France
Published online on: October 19, 2012 https://doi.org/10.3892/or.2012.2090
Pages: 355-361

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A pathological complete response (pCR) after neoadjuvant chemotherapy is observed in approximately 20% of breast cancer patients. A proteomic analysis was performed on plasma and tumor tissue before treatment to evaluate its potential impact on the prediction of response. One hundred and forty-nine breast cancer patients eligible for neoadjuvant chemotherapy were included in the study between February 2004 and January 2009 at three centers. The proteomic analysis was performed using SELDI Technology (ProteinChip CM10 pH4, IMAC-Cu and H50). Three acquisition protocols were used according to the mass range. Plasma and tumor proteomic signatures were generated using generalized ROC criteria and cross-validation. Twenty-eight (18.8%) patients out of 149 experienced a pCR according to Sataloff criteria. In the cytosol analysis, respectively 4, 2 and 8 proteins had significantly different levels of expression in the responders and non-responders using IMAC-Cu, H50 and CM10 pH4. Among the 8 proteins of interest on CM10 pH4, 2 (C1 and C7) were selected and were validated in 95.0 and 85.6% of the models. In the plasma analysis, respectively 12, 6 and 2 proteins had different levels of expression using the same proteinchips. Among the 12 plasma proteins of interest on IMAC-Cu, 2 (P1 and P7) were selected and were validated in 94.8 and 97.6% of the models. A combined proteomic signature was generated, which remained statistically significant when adjusted for hormone receptor status and Ki-67. Our results show that proteomic analysis can differentiate complete pathological responders in breast cancer patients after neoadjuvant chemotherapy.

View Figures

View References

1	Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000. View Article : Google Scholar
2	Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 21:3357–3365. 2003. View Article : Google Scholar : PubMed/NCBI
3	Roche H, Fumoleau P, Spielman M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 24:5664–5671. 2006. View Article : Google Scholar
4	Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, et al: Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res. 61:76–80. 2001.PubMed/NCBI
5	Adam BL, Qu Y, Davis JW, et al: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62:3609–3614. 2002.
6	Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:572–577. 2002. View Article : Google Scholar : PubMed/NCBI
7	Petricoin EF III, Ornstein DK, Paweletz CP, et al: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 94:1576–1578. 2002. View Article : Google Scholar : PubMed/NCBI
8	Vlahou A, Laronga C, Wilson L, et al: A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer. 4:203–209. 2003. View Article : Google Scholar : PubMed/NCBI
9	Koopmann J, Zhang Z, White N, et al: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res. 10:860–868. 2004. View Article : Google Scholar : PubMed/NCBI
10	Wadsworth JT, Somers KD, Cazares LH, et al: Serum protein profiles to identify head and neck cancer. Clin Cancer Res. 10:1625–1632. 2004. View Article : Google Scholar : PubMed/NCBI
11	Zhang Z, Bast RC Jr, Yu Y, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64:5882–5890. 2004. View Article : Google Scholar : PubMed/NCBI
12	Fung ET, Yip TT, Lomas L, et al: Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer. 115:783–789. 2005. View Article : Google Scholar : PubMed/NCBI
13	Fung ET, Thulasiraman V, Weinberger SR and Dalmasso EA: Protein biochips for differential profiling. Curr Opin Biotechnol. 12:65–69. 2001. View Article : Google Scholar : PubMed/NCBI
14	Hodgkinson VC, Eagle GL, Drew PJ, Lind MJ and Cawkwell L: Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett. 294:13–24. 2010. View Article : Google Scholar : PubMed/NCBI
15	He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF and Chang HR: Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol. 35:683–692. 2009.PubMed/NCBI
16	Sataloff DM, Mason BA, Prestipino AJ, Seinige VL, Lieber CP and Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 180:297–306. 1995.PubMed/NCBI
17	Bradford MM: Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
18	Kramar A, Farraggi D, Fortuné A and Reiser B: mROC: a computer program for combining tumour markers in predicting disease states. Comput Methods Programs Biomed. 66:199–207. 2001. View Article : Google Scholar : PubMed/NCBI
19	Kozak KR, Amneus MW, Pusey SM, et al: Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA. 100:12343–12348. 2003. View Article : Google Scholar : PubMed/NCBI
20	Gonçalves A, Esterni B, Bertucci F, et al: Postoperative serum proteomic profiles may predict metastatic relapse in high-riskprimary breast cancer patients receiving adjuvant chemotherapy. Oncogene. 25:981–989. 2006.PubMed/NCBI
21	Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 96:353–356. 2004. View Article : Google Scholar : PubMed/NCBI
22	Ricolleau G, Charbonnel C, Lodé L, et al: Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics. 6:1963–1975. 2006. View Article : Google Scholar
23	Pusztai L, Gregory BW, Baggerly KA, et al: Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. 100:1814–1822. 2004. View Article : Google Scholar
24	Zhang K, Yuan K, Wu H, et al: Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS. Appl Biochem Biotechnol. 166:753–763. 2012. View Article : Google Scholar : PubMed/NCBI
25	Dang CT and Hudis C: Preoperative chemotherapy for operable breast cancer. Diseases of the Breast. Harris JR, Lippman ME, Morrow M and Osborne CK: WoltersKluwer/Lippincott Williams &Williams; Philadelphia: pp. 715–723. 2010
26	Mailliez A, Baranzelli MC, Giard S, et al: Is there a reliable method to assess the complete pathologic response on the tumor after neo-adjuvant chemotherapy in inflammatory breast cancer toward recommendations for the pathologic process? Experience in 56 patients treated in a single institution. Breast J. 16:464–471. 2010. View Article : Google Scholar
27	Penault-Llorca F, Abrial C, Raolelfils I, et al: Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist. 13:1235–1245. 2008. View Article : Google Scholar
28	Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
29	Katz A, Saad ED, Porter P and Pusztai L: Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol. 8:55–62. 2007. View Article : Google Scholar : PubMed/NCBI
30	Liedtke C, Hatzis C, Symmans WF, et al: Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 27:3185–3191. 2009. View Article : Google Scholar : PubMed/NCBI
31	Straver ME, Glas AM, Hannemann J, et al: The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 119:551–558. 2010. View Article : Google Scholar : PubMed/NCBI
32	Tabchy A, Valero V, Vidaurre T, et al: Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 16:5351–5361. 2010. View Article : Google Scholar
33	Lee JK, Coutant C, Kim YC, et al: Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 16:711–718. 2010. View Article : Google Scholar : PubMed/NCBI